Manufacturing company Lonza announced plans to establish a new large-scale, commercial drug product fill and finish facility to support customers across the entire product life cycle. The company will invest approximately 520 million dollars in the facility.
Lonza has plans to expand inhalation services by adding capabilities at its Tampa site in the USA. The move is a part of providing bioavailability enhancement series for its global customers. The new extended services will be built upon the firm’s expertise in supporting particle engineering projects from its Bend site.